Zum Inhalt

Cerebral intraparenchymal extramedullary hematopoiesis in polycythemia vera

  • Open Access
  • 01.08.2019
  • Neuro-Images
Erschienen in:
Download

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Polycythemia vera (PV) is the most common myeloproliferative neoplasm, characterized by erythrocytosis, leukocytosis, and thrombocytosis and often associated with splenomegaly [1]. Neurological complications of PV are rare, but can include ischemic strokes, transient ischemic attacks (TIAs), and atypical TIAs [2].
Extramedullary hematopoiesis (EMH) is a compensatory physiological response of the organism to the failure of hematopoiesis at the bone marrow, which occurs commonly in patients with chronic hemolytic anemia or diseases with ineffective erythropoiesis [3]. Usually, extramedullary production of blood precursor cells occurs in the spleen, liver, or lymph nodes. However, cases with EMH in the adrenals, thymus, pleura, skin, gastrointestinal tract, and paranasal sinuses have been described [4]. Intracranial EMH is extremely rare, and only cases involving the dura mater have been described [3]. To the best of our knowledge, no cases of intracranial intraparenchymal EMH have been described.
A 48-year-old man with known polycythemia vera for 6 years presented with acute tinnitus. Six months before this, he was diagnosed with disease progression due to splenomegaly, anemia, leukocytosis (100,000 cells/μl,), and thrombocytopenia.
Magnetic resonance (MR) imaging of the brain was performed on a 1.5 T scanner (Philips Gyroscan Intera, NE), consisting of axial fluid attenuation inversion recovery (FLAIR), sagittal T1-weighted (T1WI), coronal T2-weighted (T2WI) MR images, diffusion-weighted imaging (DWI), and a post-contrast T1WI study in two planes. In the right temporal lobe, there was a T1WI isointense (Fig. 1b) and T2WI hypointense (Fig. 1c), intraparenchymal 2-cm-lesion, surrounded by a rim of T2W high-intensity perilesional edema. The lesion was adjacent to the right temporal horn. On DWI, the lesion showed a low signal. On post-contrast T1W images (Fig. 1d), there was a patchy, dot-like enhancement. There were no other brain lesions.
Fig. 1
On the initial MR exam, there was a 2-cm FLAIR hypointense (a), T1WI isointense (b), T2 hypointense (c) lesion in the right temporal lobe adjacent to the temporal horn, with perilesional edema and patchy contrast enhancement (d). At the 6-month follow-up MR scan, there was only a small scar with hemosiderin deposits (e, f)
Bild vergrößern
Elective splenectomy was performed 2 days later, and histology revealed extramedullary hematopoiesis. On a follow-up brain MR scan, 6 weeks after the initial exam, the lesion showed a significant reduction in size, with central T1W- and T2W hyperintensity and a dark peripheral rim. No edema and no contrast enhancement were detected. Six weeks later, on the last follow-up MR scan, there was only a non-enhancing linear scar with hemosiderin deposits (Fig. 1e, f). The patient’s neurological symptoms resolved completely. Three months after splenectomy, the patient underwent the first allogenic stem cell transplantation.
We present the first unique case of intracranial intraparenchymal EMH in a patient with polycythemia vera. PV is a myeloproliferative disorder, presenting with neurological complications mostly related to hypercoagulability and elevated hematocrit, such as ischemic strokes, TIAs, and atypical TIAs [2]. EMH is a compensatory, ectopic production of blood precursor cells in tissues other than bone marrow. Common sites of EMH are the liver, spleen, and lymph nodes. To date, cases of intracranial EMH have been described only in the form of extra-axial, epidural, or subdural, mass-like lesions [3]. The majority of the published cases were asymptomatic, presenting with symptoms only in cases of elevated intracranial pressure due to a tumor-like mass [5].
Imaging features of the lesions in our case were highly suggestive of extramedullary hematopoiesis; T1W isointensity and T2W hypointensity of the lesion were consistent with a high-cellularity lesion. Elevated diffusion excluded thromboembolic etiology. On SWI, the lesion showed susceptibility artifacts, suggesting the presence of blood products. Finally, there was a pattern of nonspecific, patchy enhancement, thus excluding lymphoma or sarcoid granuloma. The lesion showed reduction in size after treatment, resulting in a scar with a small hemosiderin deposition. Signs of radiological regression followed the clinical improvement of the patient.
One limitation of the study is the lack of histological proof of the diagnosis. However, imaging features of the lesion and the almost complete resolution of the lesion after splenectomy, in our opinion, exclude all potential differential diagnostic options.
The tinnitus in our patient can be explained by the extramedullary hematopoietic lesion in the temporal lobe that caused a disturbance in the network of the anterior cingulate cortex, the anterior insula, and the amygdala [6]. To conclude, although extremely rare, one should be aware of the possibility of intracranial intraparenchymal EMH in patients with myeloproliferative disorders, who present with neurological symptoms.

Acknowledgements

Open access funding provided by Medical University of Vienna.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Download
Titel
Cerebral intraparenchymal extramedullary hematopoiesis in polycythemia vera
Verfasst von
Jasmina Boban
Peter Kalhs
Majda M. Thurnher
Publikationsdatum
01.08.2019
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 5/2020
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-019-01196-2
1.
Zurück zum Zitat Spivak JL (2018) Polycythemia vera. Curr Treat Options Oncol 19(2):12CrossRef
2.
Zurück zum Zitat Michiels JJ, Berneman Z, Schroyens W et al (2006) Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 17(8):528–544CrossRef
3.
Zurück zum Zitat Merchant R, Choudhari AJ, Verma M, Patkar DP, Doctor P (2018) Intracranial hematopoiesis in beta thalassemia: a case series. Ind J Pediatr 85(8):679–681CrossRef
4.
Zurück zum Zitat Ginzel AW, Kransdorf MJ, Peterson JJ, Garner HW, Murphey MD (2012) Mass-like extramedullary hematopoiesis: imaging features. Skelet Radiol 41:911–916CrossRef
5.
Zurück zum Zitat Eskazan AE, Ar MC, Baslar Z (2012) Intracranial extramedullary hematopoiesis in patients with thalassemia: a case report and review of the literature. Transfusion 52(8):1715–1720CrossRef
6.
Zurück zum Zitat Langguth B, Kreuzer PM, Kleinjung T, De Ridder D (2013) Tinnitus: causes and clinical management. Lancet Neurol 12:920–930CrossRef

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Hochwirksame MS-Therapie ab 52 Jahren ohne klaren Vorteil

Ein Therapiebeginn mit einer hochwirksamen MS-Arznei verspricht besonders guten Schutz vor neuen Schüben und der Krankheitsprogression. Mit knapp über 50 Jahren zeigten sich in einer Registeranalyse aber keine Vorteile mehr gegenüber einer moderat wirksamen Behandlung.

Auch bei Schallleitungsschwerhörigkeit steigt das Risiko für Demenz

Das Risiko einer Demenz scheint bei Schwerhörigkeit zu steigen, unabhängig davon, wo der Schaden liegt. Darauf deuten die Ergebnisse einer Studie zur Schalleitungsschwerhörigkeit hin.

KI-Chatbots bieten 24/7-Sprechstunde für Patienten

Medizinischen Rat von Chatbots auf der Basis sogenannter künstlicher Intelligenz haben laut Umfragen bereits knapp die Hälfte aller Erwachsenen schon einmal eingeholt. Welche Chancen und Risiken birgt das?

Schützt Optimismus vor Demenz?

  • 14.04.2026
  • Demenz
  • Nachrichten

Wer insgesamt zuversichtlicher aufs Leben blickt, trägt ein geringeres Risiko, später einmal an Demenz zu erkranken als pessimistischere Zeitgenossen. Dafür sprechen zumindest Ergebnisse einer Längsschnittdatenanalyse aus den USA. Ob mehr Optimismus allerdings tatsächlich einer Demenz vorbeugt, bleibt unklar.   

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Bildnachweise
Die Leitlinien für Ärztinnen und Ärzte, Ältere Frau mit Multipler Sklerose, die mit verschiedenen Hilfsmitteln, darunter auch technische Geräte, alltägliche Wartungsarbeiten verrichtet./© eyecrave / Getty Images / iStock (Symbolbild mit Fotomodell), Vater recherchiert am Smartphone/© Elnur / stock.adobe.com (Symbolbild mit Fotomodell), Alter Mann entspannt sich im Grünen/© koldunova_anna / stock.adobe.com (Symbolbild mit Fotomodell)